Product · #6 of 27 · menopause + weight
Estroven Menopause Relief + Weight Management
Capsule from Estroven, made by i-Health (dsm-firmenich). Daily serving: 1 capsule.
Last updated · Price and ratings checked Nov 19, 2026
In short: Estroven Menopause Relief + Weight Management scores 58.4/100 in our ranking (#6 of 27). It costs $0.63 a day at the regular price. Evidence: soy isoflavones 56 mg + black cohosh 40 mg; no product trial; best ingredient grade B- (Soy isoflavones & genistein). No NSF registry listing was confirmed.
Pros
- Low cost: $0.63 a day at the label dose.
- Widely reviewed: ★ 4.3 from 16,709 Amazon ratings.
- Evidence: soy isoflavones 56 mg + black cohosh 40 mg; no product trial.
Cons
- No NSF registry listing confirmed.
- Contains black cohosh: rare liver-injury reports, and adulteration is common across the category.
- Legal or regulatory history: see flags below.
Flags
Class actionWatchdog complaintLiver caution
Score breakdown
Full label: what's in it
| Ingredient (as labeled) | Per day | Evidence page |
|---|---|---|
| Black cohosh root extract (standardization not stated) | 40 mg | Black cohosh C |
| Soy isoflavones | 56 mg | Soy isoflavones & genistein B- |
| CQR-300 Cissus quadrangularis stem & leaf extract | 300 mg | Not in our evidence library |
Label read from an older (2022) Supplement Facts image still shown on the product page; the current label was not confirmed. Unverified
Evidence
Our evidence score: 26/40, because: soy isoflavones 56 mg + black cohosh 40 mg; no product trial.
Product-level research: we found no published trial of this exact product, so its evidence comes from studies of its ingredients.
Ingredient evidence
- Black cohosh C (40 mg here)
Black cohosh is the most-studied herb for occasional hot flashes and night sweats associated with menopause*. Independent trials and a Cochrane review found no clear benefit over placebo, other reviews found a small one, and rare liver-injury reports exist. The Menopause Society 2023: Not recommended (Level I) – 'insufficient evidence to support use for VMS'. - Soy isoflavones & genistein B- (56 mg here)
Soy isoflavones (including genistein) are the most widely studied supplement group for occasional hot flashes associated with menopause*. Meta-analyses find modest average effects, such as about 20% fewer hot flashes than placebo in one analysis, and results vary between trials. The Menopause Society 2023: Not recommended (Level II) – mixed evidence.
Studies
Studies on its ingredients (19)
-
Black cohosh (Cimicifuga spp.) for menopausal symptoms.
An independent Cochrane review pooled 16 trials with about 2,000 women taking black cohosh (usually 40 mg a day for around 5 months). Women taking black cohosh did not have fewer hot flashes than women on a dummy pill, and the reviewers called the safety data inconclusive.
- Who
- 16 RCTs, 2,027 women
- Dose
- median 40 mg/day black cohosh extract
- Duration
- mean 23 weeks
- Result
- No difference vs placebo in hot-flush frequency (MD +0.07/day; 95% CI -0.43 to 0.56; 3 trials, 393 women) or symptom scores; hormone therapy beat black cohosh.
- Funding
- Cochrane review (independent). Independent / academic
-
Black cohosh extracts in women with menopausal symptoms: an updated pairwise meta-analysis.
A 2023 analysis of 22 studies (about 2,300 women) found black cohosh extracts did somewhat better than placebo for overall menopause symptoms and hot flashes, with a small-to-moderate effect. It did not help anxiety or low mood, and the studies varied a lot in product and quality.
- Who
- 22 articles, 2,310 women
- Dose
- various black cohosh extracts
- Duration
- various
- Result
- Pooled improvement vs placebo in overall menopausal symptoms (Hedges g 0.58) and hot flashes (g 0.32); no significant effect on anxiety or depression.
- Funding
- Academic; one author reported speaker fees from supplement/pharma companies incl. Cimic. Some author ties
-
Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence.
This review looked only at the specific black cohosh extract in Remifemin and found it beat placebo for menopause symptoms, especially at higher doses or combined with St John's wort. Several authors work for the company that makes Remifemin, so read it as a manufacturer-backed summary.
- Who
- 35 studies + 1 MA, 43,759 women (13,096 on iCR)
- Dose
- isopropanolic extract (iCR, Remifemin), 20–>40 mg/day
- Duration
- various
- Result
- SMD -0.69 vs placebo for neurovegetative/psychological symptoms; larger effect at higher dose and with St John's wort; no hepatotoxicity signal in trial data.
- Funding
- Co-authored by staff of Schaper & Brümmer (maker of Remifemin) – manufacturer-affiliated. Industry-linked
-
Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms.
About 300 women with menopause symptoms took Remifemin-type black cohosh (40 mg a day) or a dummy pill for 12 weeks. Symptom scores improved more with black cohosh, mostly in women early in menopause, and side effects were similar to placebo.
- Who
- 304 women
- Dose
- iCR (Remifemin) equivalent to 40 mg root/day
- Duration
- 12 weeks
- Result
- More effective than placebo on the Menopause Rating Scale (P<.001), mainly in early menopause; hot-flush subscore was the most responsive.
- Funding
- Funding not stated in the abstract (study of the manufacturer's extract). Funding not stated
-
Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1.
In a publicly funded US trial, 132 women took black cohosh (20 mg twice a day) or placebo for 4 weeks each. Hot flashes dropped slightly more on placebo than on black cohosh, so the trial found no benefit.
- Who
- 132 women (history of or concern about breast cancer; crossover)
- Dose
- black cohosh 20 mg twice daily
- Duration
- two 4-week periods (crossover)
- Result
- Hot-flash frequency fell 17% on black cohosh vs 26% on placebo (P=.36) – no benefit.
- Funding
- NCCTG/NCI cooperative group (public funding). Independent / academic
-
Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial.
The US government-funded HALT study followed 351 women for a year. Black cohosh (160 mg a day), a 10-herb blend, and the blend plus more soy food did no better than a dummy pill for hot flashes, while hormone therapy clearly worked.
- Who
- 351 women aged 45–55
- Dose
- black cohosh 160 mg/day; multibotanical; multibotanical + soy diet; hormone therapy; placebo
- Duration
- 12 months
- Result
- No herbal arm differed from placebo at 3, 6 or 12 months (<1 hot flash/day difference); hormone therapy reduced ~4 symptoms/day vs placebo.
- Funding
- US NIH (NCCAM/NIA) – HALT study, independent. Independent / academic
-
Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial.
In a year-long, government-funded trial, women took black cohosh, red clover, hormone therapy or a dummy pill. Only hormones beat placebo for hot flashes; both herbs looked safe but did not reduce hot flashes more than placebo.
- Who
- 89 women (4 arms)
- Dose
- standardized black cohosh and red clover extracts vs CEE/MPA vs placebo
- Duration
- 12 months
- Result
- Hot-flash reduction: black cohosh 34%, red clover 57%, placebo 63%, hormones 94%; neither botanical beat placebo. Both appeared safe over 12 months.
- Funding
- NIH (NCCAM/ODS) botanical center, University of Illinois – independent. Independent / academic
-
Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial.
122 women took a different (ethanol-based) black cohosh extract or placebo for 12 weeks. Overall it did not beat placebo; only women with more severe symptoms seemed to benefit, which is a weaker, after-the-fact finding.
- Who
- 122 women with ≥3 hot flashes/day
- Dose
- dried ethanolic black cohosh extract (non-Remifemin)
- Duration
- 12 weeks
- Result
- No superiority over placebo overall; benefit only in subgroup with moderate–severe symptoms (Kupperman ≥20: -47% vs -21%).
- Funding
- Not stated in abstract. Funding not stated
-
Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract.
This analysis of 5 trials found no change in liver blood tests in women taking the Remifemin extract for up to 6 months. It was written by the manufacturer and covers only short-term use.
- Who
- 5 RCTs, 1,117 women
- Dose
- iCR 40–128 mg/day
- Duration
- 3–6 months
- Result
- No effect on liver enzymes (AST/ALT) vs reference groups.
- Funding
- Written by Schaper & Brümmer (Remifemin maker) staff. Industry-linked
-
United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity.
The US Pharmacopeia reviewed 30 reports of liver injury in people using black cohosh. It could not prove black cohosh caused them but recommended a label warning to stop and see a doctor if liver symptoms appear.
- Who
- 30 case reports of liver damage
- Dose
- various products
- Duration
- n/a
- Result
- All 30 liver cases rated 'possible' (none probable/certain); USP recommended a cautionary liver label.
- Funding
- US Pharmacopeia expert committee (independent standard-setter). Independent / academic
-
Black cohosh and breast cancer: a systematic review.
A systematic review of black cohosh and breast cancer found no sign it increases breast-cancer risk, but also no proof it reduces hot flashes in women who have had breast cancer.
- Who
- 26 studies (14 RCTs)
- Dose
- various
- Duration
- various
- Result
- No evidence black cohosh raises breast-cancer risk; no proven hot-flash benefit in breast-cancer patients vs placebo.
- Funding
- Academic (Canadian naturopathic/academic group). Independent / academic
-
Actaea racemosa L. Is More Effective in Combination with Rhodiola rosea L. for Relief of Menopausal Symptoms: A Randomized, Double-Blind, Placebo-Controlled Study.
220 women in Georgia took black cohosh alone, black cohosh plus Rhodiola, or placebo for 12 weeks; the combination worked best. An author is paid by the company that sells the combination.
- Who
- 220 women
- Dose
- black cohosh 6.5 mg; black cohosh 500 mg; Rhodiola+black cohosh (Menopause Relief EP); placebo
- Duration
- 12 weeks
- Result
- Rhodiola+black cohosh beat black cohosh alone and placebo on all symptom scales.
- Funding
- Author has contract with Europharma USA (seller) and heads Phytomed AB. Industry-linked
-
Complementary therapies for management of menopausal symptoms: a systematic review to inform the update of the International Menopause Society recommendations on women's midlife health.
A 2026 International Menopause Society evidence review rated black cohosh's benefit for hot flashes as moderate-certainty and most other supplements as low-certainty.
- Who
- 158 studies
- Dose
- various
- Duration
- n/a
- Result
- Moderate-certainty evidence supports black cohosh for vasomotor/menopausal symptoms and vitamin D for fracture risk; most complementary therapies low/very-low certainty.
- Funding
- International Menopause Society review. Independent / academic
-
Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone.
244 Chinese women took Remifemin-type black cohosh or the hormone-like drug tibolone for 12 weeks. Symptom scores fell similarly in both groups, but there was no placebo group, so the size of the true effect is unclear.
- Who
- 244 Chinese women
- Dose
- iCR (Remifemin) equivalent to 40 mg/day vs tibolone 2.5 mg/day (no placebo)
- Duration
- 12 weeks
- Result
- Kupperman Index fell similarly with iCR and tibolone; iCR better tolerated.
- Funding
- Not stated in abstract. Funding not stated
-
Phytoestrogens for menopausal vasomotor symptoms.
An independent Cochrane review of 43 trials found no conclusive proof that phytoestrogens (soy, red clover) reduce hot flashes. High-genistein soy extracts looked more promising, and placebo effects were large.
- Who
- 43 RCTs, 4,364 women
- Dose
- various phytoestrogens
- Duration
- various
- Result
- No conclusive evidence of reduced hot flushes; Promensil (red clover) not better than placebo (MD -0.93/day, NS); genistein >30 mg/day may help; strong placebo effect.
- Funding
- Cochrane review (independent). Independent / academic
-
Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials.
Pooling 17 trials, soy isoflavone supplements (about 54 mg a day) cut hot-flash frequency by about a fifth more than placebo. Products higher in genistein worked better. Results varied widely between studies.
- Who
- 17 RCTs in meta-analysis
- Dose
- median 54 mg isoflavones/day
- Duration
- 6 weeks–12 months
- Result
- Hot-flash frequency -20.6% and severity -26.2% vs placebo; >18.8 mg genistein about twice as effective.
- Funding
- Academic (Japan/US); funding not stated in abstract. Funding not stated
-
Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis.
A JAMA analysis of 62 studies found plant estrogens such as soy cut about one hot flash a day compared with placebo – a modest effect – and most studies were of low quality.
- Who
- 62 studies, 6,653 women
- Dose
- phytoestrogens and other plant therapies
- Duration
- various
- Result
- Phytoestrogens: -1.31 hot flashes/day; soy isoflavones -0.79/day; 74% of RCTs at high risk of bias.
- Funding
- Academic (Erasmus MC); industry co-funding reported in paper is not verified here. Industry-linked
-
Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study.
Italian women took high-dose soy isoflavones (150 mg a day) or placebo for 5 years. A small number on soy developed thickening of the womb lining (3.4% vs 0%), so long-term high doses deserve caution.
- Who
- 376 women with intact uterus
- Dose
- soy isoflavones 150 mg/day
- Duration
- 5 years
- Result
- Endometrial hyperplasia in 3.37% on soy vs 0% placebo; no cancers.
- Funding
- Not stated in abstract. Funding not stated
-
Soy and isoflavones consumption and breast cancer survival and recurrence: a systematic review and meta-analysis.
Studies following women with breast cancer found eating soy was linked to lower recurrence, not higher. These looked at soy food, not concentrated supplements.
- Who
- 12 cohort studies, 37,275 breast-cancer patients
- Dose
- dietary soy/isoflavone intake
- Duration
- observational
- Result
- Pre- and post-diagnosis soy intake associated with lower recurrence; no harm signal.
- Funding
- Academic. Independent / academic
The Menopause Society's 2023 statement is in the study library.
Price
| Regular one-time price | $18.99 (30 units, 30 days at label dose) |
|---|---|
| Cost per day | $0.63 |
| Subscription | Amazon S&S $14.35 |
| Price notes | 30 ct $18.99; 60 ct $34.99. Amazon B01ANSJV80 list $18.79 (BF $15.11) |
| In stock when checked | Yes |
| Checked | Nov 19, 2026 |
Ratings
Amazon: ★ 4.3 from 16,709 ratings on Amazon (checked Nov 19, 2026)
Star ratings reflect buyer satisfaction, not clinical effect.
Certifications and claims
Verified in a public registry
- No registry listing found.
Claims made by the brand
- “hormone-free” Brand claim
- “drug-free” Brand claim
- “contains soy” Brand claim
Registry check: NSF/ANSI 173 (searched 'Estroven', 'i-Health'): not found
Who's behind it
| Brand | Estroven |
|---|---|
| Owner / company | i-Health, Inc. (Cromwell, CT), part of the dsm-firmenich group (estroven.com footer '© 2026 dsm-firmenich group'). |
| Founders | Not stated on the pages we read. |
| Where it's made | Older label: 'Made in the USA with US and imported materials' (Weight Management SFP); not stated for others. |
| Medical advisors named |
|
| Source | estroven.com |
Flags & safety
Legal, regulatory and quality flags
- Class action Arnold v. I-Health, Inc. (C.D. Cal. 2:26-cv-01282, filed 2026) alleges Estroven Mood Boost and Stress Relief claims are false/misleading (not the Complete SKU). classaction.org
- TINA.org warning letter to i-Health re menopause marketing (Oct 2024). truthinadvertising.org
- Contains black cohosh (see black cohosh adulteration/liver caution in general notes).
- Systematic review (Natural Product Reports 2024): 42.2% of 322 black cohosh samples across 78 publications adulterated/mislabeled, mainly with Asian Actaea species. pubs.rsc.org
- DNA barcoding (J AOAC 2012): 9 of 36 (25%) US black cohosh supplements matched Asian Actaea. pubmed.ncbi.nlm.nih.gov
- ConsumerLab 'Menopause Supplements Review' (soy/red clover isoflavones, black cohosh, progesterone cream) last updated 2026-10-29; product results are members-only (not accessed). Public summary: ≥50 mg soy isoflavones or ≥15 mg genistein / 28 mg daidzein for effect; only 1/3–1/2 of women are equol producers. Past rounds found products with 30–59% of listed isoflavones and a black cohosh product with lead. consumerlab.com
Ingredient safety notes
- Black cohosh: Rare liver injury reports (USP: 30 cases 'possible' causality; ODS: ≥83 cases worldwide, causality unproven). USP-recommended label: discontinue if liver disorder or symptoms of liver trouble. No evidence of increased breast-cancer risk (Fritz 2014), but safety after breast cancer not established (NCCIH). Possible interaction with statins (NCCIH).
- Soy isoflavones & genistein: Soy is a common allergen. In a 5-year trial of 150 mg/day isoflavones, endometrial hyperplasia occurred in 3.4% vs 0% on placebo (Unfer 2004). Cohort studies of soy foods in breast-cancer survivors link them with lower recurrence and show no harm signal, but the safety of concentrated isoflavone supplements after breast cancer is uncertain (NCCIH).
Not verified
- Current label (we read an older 2022 label image). Unverified
Sources
Talk to a clinician first
The Menopause Society's 2023 nonhormone position statement does not recommend any dietary supplement or herbal remedy for hot flashes, because the research is limited or mixed. Hormone therapy is an option for many women, and the statement lists non-hormonal options with evidence behind them: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III).
If hot flashes, night sweats, sleep or mood are affecting your life, talk to a clinician first. If you still want to try a supplement, the rankings below show what is actually in each one, what the research found, and who is behind it. Sources: position statement (PDF) · PubMed.
*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.